New concerns about medicines often prompt regulators to issue safety advisories, but a new review finds that not all advisories are created equal.

An analysis of such alerts issued by regulators in four countries — the U.S. Food and Drug Administration, Health Canada, the U.K. Medicines and Healthcare products Regulatory Agency, and the Australian Therapeutic Goods Administration — found the “overall frequency with which the regulators issued advisories differed significantly,” a team of researchers wrote in JAMA Internal Medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy